Alessandro Di Sanzo

Articles by Alessandro Di Sanzo

TIP134 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From ER+/HER2– Breast Cancer

ByNuhad Ibrahim, MD,Eva Ciruelos Gil,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Tomer Wasserman,Erika P. Hamilton, MD

May 4th 2026

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

ByNuhad Ibrahim, MD,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Eva Ciruelos Gil,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Kathy Puyana Theall,Erika P. Hamilton, MD

August 3rd 2024

Latest Updated Articles

Trending on CancerNetwork

Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma

FDA Clears TriNav Advance for Expanded Liver Embolization Access

Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials